Title: Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
Journal: Journal of medicinal chemistry 20140313
Title: Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study.
Journal: Clinical pharmacokinetics 20120701
Title: Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
Journal: Bioorganic & medicinal chemistry letters 20120415
Title: Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.
Journal: Gastroenterology 20120401
Title: Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.
Journal: Journal of hepatology 20111101
Title: Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.
Journal: Gastroenterology 20110901
Title: Second-wave protease inhibitors: choosing an heir.
Journal: Clinics in liver disease 20110801
Title: Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
Journal: Journal of hepatology 20110601
Title: Emerging therapeutic options in hepatitis C virus infection.
Journal: The American journal of managed care 20110301
Title: Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
Journal: Antimicrobial agents and chemotherapy 20101201
Title: Curing hepatitis C with pills: a step toward global control.
Journal: Lancet (London, England) 20101030
Title: Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Journal: Lancet (London, England) 20101030
Title: Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection.
Journal: Current opinion in investigational drugs (London, England : 2000) 20100801
Title: Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
Journal: Antimicrobial agents and chemotherapy 20080301
Title: Imhof I, et al. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191).Hepatology. 2011 Apr;53(4):1090-9.
Title: Seiwert, Scott D., et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrobial Agents and Chemotherapy (2008), 52(12), 4432-4441.
Title: Bartels DJ, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis. 2008 Sep 15;198(6):800-7.
Title: Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.
